SparingVision Presents Validating Data of its Lead Gene Therapy Programs, SPVN06 and SPVN20, at ESGCT 2022
SparingVision Presents Validating Data of its Lead Gene Therapy Programs, SPVN06 and SPVN20, at ESGCT 2022…
SparingVision Presents Additional Data on its Breakthrough Gene Therapy Approach SPVN06 at ASGCT 2022 Data…
SparingVision Presents Progress of its Lead Gene Therapy Program, SPVN06, at ARVO 2022 Paris, May…
SparingVision announces Oral Presentation of SPVN06 Data at ASGCT 2022 Paris, May 3, 2022 –…
SparingVision to Highlight Progress of its Lead Gene Therapy Program SPVN06 and Research on Retinitis…
SparingVision to Present at the 40th Annual J.P. Morgan Healthcare Conference Paris, January 6…